DAPA-CKD
Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease...
Description
In the DAPA-CKD cohort the efficacy and safety was evaluated of dapagliflozin in patients with chronic kidney disease....
General Design
- Type
- Clinical trial
- Start/End data collection
- 2017 until 2020
- PID
- https://doi.org/10.34760/68527c7007c8f
- External identifiers
- NCT03036150
Population
- Main medical condition
- XIV Diseases of the genitourinary system
- N17-N19 Renal failure
- N18.4 Chronic kidney disease, stage 4
- N18 Chronic kidney disease
- N18.2 Chronic kidney disease, stage 2
- N18.3 Chronic kidney disease, stage 3
Organisations
Additional organisations
Contributors
- prof. dr. HJ (Hiddo) HJLH HeerspinkUniversity Medical Center Groningenh.j.lambers.heerspink@umcg.nl
Principal Investigator, Primary contact
Available Data & Samples
Sample categories
- Blood
- Plasma
Areas of information
- Socio-demographic and economic characteristics
- Age/birthdate
- Sex/gender
- Ethnicity, race and religion
- Lifestyle and behaviours
- Tobacco
- Medication and supplements
- Medication and supplement intake
- Death
- Vital status
- Cause of death
- Laboratory measures
- Biochemistry
- Immunology
Subpopulations
List of subpopulations for this resource...
| Name | Description | Number of participants | |
|---|---|---|---|
No results for current selection |
Collection events
List of collection events defined for this resource...
| Name | Description | Participants | Start end year | |
|---|---|---|---|---|
No results for current selection |